kidney disease and semaglutide FLOW clinical Trial (funded by Novo Nordisk): showed 24% reduction in the risk of disease-related events in people with type 2 diabetes chronic kidney compared to placebo. Investigators Effects of Once-Weekly Semaglutide on
Description
The data on this approach is limited
Report these to your medical team
Subject to medical eligibility
The plastic in syringes can sometimes interact with the peptide, and there is a higher risk of contamination
They are not approved for use in individuals with type 1 diabetes or diabetic ketoacidosis
116 demonstrated that the use of dual therapy of metformin, whether with GLP-1RAs or TZDs, was superior to monotherapy in improving hyperandrogenemia in women with PCOS
